Shanghai-based CRO, ChemPartner, a subsidiary of Chinese biotech Services Outsourcing company, ShangPharma, has signed a research services agreement with China-based oncology specialists, Shenogen Pharma, to develop therapeutic antibodies for use in the treatment of various forms of cancer.